UPCOMING STUDIES

Lessening Organ Dysfunction with VITamin C: LOVIT Trial

PI: Dr. Oleksa Rewa  ClinicalTrials.gov: NCT03680274

The purpose of this parallel blinded randomized controlled study is to determine if the administration of vitamin C decreases the harmful effects of the infection on organs and improve health status more rapidly than placebo. It is anticipated that about 800 people will take part in this study from 25 ICUs across Canada.

We plan to enroll at least 50 patients in General Systems ICU.

Primary Outcome: Death or persistent organ dysfunction at 28 days.

Study Intervention:
Experimental Arm: infusion of vitamin C 50mg/kg every 6 hrs for 96 hrs
Control Arm: placebo

Inclusion Criteria:
• ≥ 18 years old
• Has a proven or suspected infection as the main diagnosis
• Currently treated with continuous IV infusion of vasopressors

Exclusion Criteria:
• 24 hours since ICU admission
• Known Glucose-6-phosphate dehydrogenase (G6PD) deficiency
• Allergy to vitamin C
• Known kidney stones within the past 1 year
• Received any IV vitamin C during this hospitalization unless incorporated in parenteral nutrition
• Expected death or withdrawal of life-sustaining treatments within 48 hours

Site Status: We are currently awaiting for approvals from the University of Alberta Human Research Ethics Board and NACTRC.

We anticipate our site will be released to begin enrolling by June 2019.

Completed Studies

A special congratulations to Lorena McCoshen and Dr. Wendy Sligl for enrolling the last study participant for PROSPECT Trial.

A total of 2650 patients were enrolled from ICUs in Canada and the United States of America.

A total of 27 patients were enrolled in the General Systems ICU from March 2017 to March 2019.

We look forward to seeing the results of the study once they are published.

Congratulations

Dr. Sean Bagshaw 2019 EZSMA Researcher of the Year Award recipient!

Enrollment Updates:
ALFSG: 70
BALANCE: 52
PROSPECT: 27
ROTEM: 1
STARRT-AKI
GSICU: 35
CV-ICU: 3

Publications
PREVENT Trial was recently published in The New England Journal of Medicine

https://doi.org/10.1056/NEJMo1816150

A total of 6 patients were enrolled in the General Systems ICU from September 2017 to August 2018.

To find out more about any study or ways you can be involved, contact Dr. Sean Bagshaw, Director of Research at 780-248-1256  
Nadia Baig, Research Manager at 780-492-3817, or visit our website at www.ualberta.ca/critical-care/research.